A detailed history of Edgemoor Investment Advisors, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Edgemoor Investment Advisors, Inc. holds 2,150 shares of AMGN stock, worth $681,356. This represents 0.06% of its overall portfolio holdings.

Number of Shares
2,150
Previous 2,225 3.37%
Holding current value
$681,356
Previous $632,000 6.17%
% of portfolio
0.06%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$262.75 - $319.31 $19,706 - $23,948
-75 Reduced 3.37%
2,150 $671,000
Q1 2024

May 09, 2024

SELL
$268.87 - $324.56 $18,820 - $22,719
-70 Reduced 3.05%
2,225 $632,000
Q1 2023

May 09, 2023

BUY
$225.79 - $275.2 $903 - $1,100
4 Added 0.17%
2,295 $554,000
Q4 2022

Feb 07, 2023

BUY
$229.03 - $291.01 $40,996 - $52,090
179 Added 8.48%
2,291 $601,000
Q2 2022

Aug 04, 2022

BUY
$230.71 - $256.74 $45,449 - $50,577
197 Added 10.29%
2,112 $514,000
Q1 2022

May 12, 2022

BUY
$219.27 - $242.57 $58,106 - $64,281
265 Added 16.06%
1,915 $463,000
Q4 2021

Feb 09, 2022

BUY
$198.88 - $227.6 $58,470 - $66,914
294 Added 21.68%
1,650 $371,000
Q3 2021

Nov 02, 2021

SELL
$212.27 - $248.7 $2,334 - $2,735
-11 Reduced 0.8%
1,356 $288,000
Q2 2021

Aug 11, 2021

SELL
$233.58 - $259.14 $700 - $777
-3 Reduced 0.22%
1,367 $333,000
Q1 2021

May 12, 2021

BUY
$221.91 - $258.6 $1,997 - $2,327
9 Added 0.66%
1,370 $341,000
Q1 2020

May 06, 2020

BUY
$182.24 - $241.7 $2,004 - $2,658
11 Added 0.81%
1,361 $276,000
Q4 2018

Jan 31, 2019

SELL
$178.4 - $208.25 $44,600 - $52,062
-250 Reduced 15.63%
1,350 $263,000
Q2 2018

Aug 02, 2018

SELL
$166.05 - $186.51 $17,103 - $19,210
-103 Reduced 6.05%
1,600 $295,000
Q4 2017

Feb 07, 2018

BUY
$168.79 - $188.59 $287,449 - $321,168
1,703
1,703 $316,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $170B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Edgemoor Investment Advisors, Inc. Portfolio

Follow Edgemoor Investment Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgemoor Investment Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Edgemoor Investment Advisors, Inc. with notifications on news.